Prostate Cancer Diagnostics Market Expected To Reach USD 7,112.2 Million By 2027 With Top Players Like Abbott Laboratories, Siemens Healthineers, F. Hoffman La Roche and Others

Prostate Cancer Diagnostics Market Expected To Reach USD 7,112.2 Million By 2027 With Top Players Like Abbott Laboratories, Siemens Healthineers, F. Hoffman La Roche and Others

“Reports And Data”
The rising incidence of prostate cancer is one of the significant factors influencing the growth of the diagnostic procedures for the disease.Prostate Cancer Diagnostics Market Size – USD 2,801.7 Million in 2019, Market Growth – CAGR of 12.3%, Market Trends – Increasing awareness about cancer diagnosis at an early stage.

The global prostate cancer diagnostics market is forecasted to reach USD 7,112.2 Million by 2027, according to a new report by Reports and Data. The prostate cancer diagnostics market is observing demand attributed to the rising incidence of prostate cancer. It is the most common cause of death occurring as a result of cancer in American men. It has been found that nearly 1 out of 41 men die of prostate cancer. According to recent estimations, around 33,330 men will die of the disease in the year 2020.

Increasing awareness about cancer diagnosis at an early stage is a significant factor driving the market growth. A majority of prostate cancers or about 90.0% cases are detected when the disease is in the prostate gland and the nearby organs, and for such cases, the 5-year survival rate is about 100.0%, whereas the 5-year survival rate for the cases in which the disease has spread to other body parts is 31.0%.

The COVID-19 impact:
The COVID-19 pandemic has made it essential to repurpose the operating rooms for surgeries into intensive care units (ICUs) and pushed hospitals to accommodate patients beyond their full capacity of beds. As a result, in several cases, cancer patients’ diagnostics and treatment were categorized as non-urgent. Further, the psychological influence of postponed diagnosis as a result of the COVID-19 pandemic cannot be undermined as when psychological, physical, and social health of patients are handled in a positive way, chances of patients’ survival have been seen to improve from a state of illness towards recovering from the disease. COVID-19 has had a significant and negative impact on cancer treatment and research, making a new health emergency for cancer patients’ management a necessity.

Get a sample of the report @

Further key findings from the report suggest

  • Adenocarcinomas develop in the cells of the gland, which line the prostate gland and are the most commonly occurring prostate cancer, with about everyone suffering from the disease has this type.
  • PCA3 is a biomarker beneficial in improving the precision of prostate cancer diagnostics. The biomarker is preferred, due to its fairly high sensitivity and specificity during the diagnostic procedures.
  • Hospitals & clinics dominated the market in 2019. The factors including well-resourced operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals.
  • North America contributed to the largest market share in 2019. The market dominance is owing to the higher acceptance of advanced technologies, well-established healthcare diagnostic facilities, the surging incidence of prostate cancer, and the enactment of numerous initiatives for raising awareness about the disease in the region.
  • Key participants include Abbott Laboratories, Siemens Healthineers, F. Hoffman La Roche Ltd., Danaher Corporation, Agilent Technologies, Myriad Genetics Inc., Becton, Dickinson, and Company, Diasorin SPA, Genomic Health, and Beckman Coulter Inc., among others.

Buy Now:

For the purpose of this report, Reports and Data has segmented into the global prostate cancer diagnostics on the basis of prostate cancer type, test type, end-user, and region:

Prostate Cancer Type Outlook (Revenue, USD Billion; 2017-2027)

  • Acinar Adenocarcinoma
  • Ductal Adenocarcinoma
  • Transitional Cell (or Urothelial) Cancer
  • Squamous Cell Cancer
  • Small Cell Prostate Cancer
  • Others

Test Type Outlook (Revenue, USD Billion; 2017-2027)

  • Preliminary Tests
  • Confirmatory Tests
    1. PCA3
    2. Transrectal Ultrasound
    3. Biopsy

End-User Outlook (Revenue, USD Billion; 2017-2027)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

Regional Outlook (Revenue, USD Billion; 2017-2027)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Rest of APAC
  • MEA
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • Latin America
    • Brazil
    • Rest of LATAM

To identify the key trends in the industry, click on the link below:

Table Of Content:

Chapter 1.    Market Synopsis
    1.1.    Market Definition
    1.2.    Research Scope & Premise
    1.3.    Methodology
    1.4.    Market Estimation Technique
Chapter 2.    Executive Summary
   2.1.    Summary Snapshot, 2019-2027
Chapter 3.    Indicative Metrics
Chapter 4.    Prostate Cancer Diagnostics Market Segmentation & Impact Analysis
    4.1.    Prostate Cancer Diagnostics Market Material Segmentation Analysis
    4.2.    Industrial Outlook
         4.2.1.    Market indicators analysis
         4.2.2.    Market drivers analysis
            Rising occurrences of cancer
            Growing geriatric population

Chapter 9.    Competitive Landscape
    9.1.    Market Revenue Share By Manufacturers
    9.2.    Manufacturing Cost Breakdown Analysis
    9.3.    Mergers & Acquisitions
    9.4.    Market positioning
    9.5.    Strategy Benchmarking
    9.6.    Vendor Landscape
Chapter 10.     Company Profiles                    
    10.1.    Abbott Laboratories
            10.1.1.    Company Overview
            10.1.2.    Financial Performance
            10.1.3.    Technology Insights
            10.1.4.    Strategic Initiatives
    10.2.    Siemens Healthineers
            10.2.1.    Company Overview
            10.2.2.    Financial Performance
            10.2.3.    Technology Insights
            10.2.4.    Strategic Initiatives
    10.3.    F. Hoffman La Roche Ltd.
            10.3.1.    Company Overview
            10.3.2.    Financial Performance
            10.3.3.    Technology Insights
             10.3.4.    Strategic Initiatives
    10.4.    Danaher Corporation
            10.4.1.    Company Overview
            10.4.2.    Financial Performance
            10.4.3.    Technology Insights
            10.4.4.    Strategic Initiatives
    10.5.    Agilent Technologies
            10.5.1.    Company Overview
            10.5.2.    Financial Performance
            10.5.3.    Technology Insights
            10.5.4.    Strategic Initiatives
    10.6.    Myriad Genetics Inc.
           10.6.1.    Company Overview
           10.6.2.    Financial Performance
           10.6.3.    Technology Insights
           10.6.4.    Strategic Initiatives
    10.7.    Becton, Dickinson, and Company
            10.7.1.    Company Overview
            10.7.2.    Financial Performance
            10.7.3.    Technology Insights
            10.7.4.    Strategic Initiatives


About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development.

Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States